Prevalence of pulmonary embolism in patients with COVID-19 at the time of hospital admission
M Jevnikar, O Sanchez, R Chocron… - European …, 2021 - Eur Respiratory Soc
A high prevalence of venous thromboembolism (VTE) has been reported during intensive
care unit (ICU) hospitalisation in patients with severe coronavirus disease 2019 (COVID …
care unit (ICU) hospitalisation in patients with severe coronavirus disease 2019 (COVID …
The intersection of obesity and (long) COVID-19: Hypoxia, thrombotic inflammation, and vascular endothelial injury
M Xiang, X Wu, H Jing, VA Novakovic… - Frontiers in cardiovascular …, 2023 - frontiersin.org
The role of hypoxia, vascular endothelial injury, and thrombotic inflammation in worsening
COVID-19 symptoms has been generally recognized. Damaged vascular endothelium plays …
COVID-19 symptoms has been generally recognized. Damaged vascular endothelium plays …
[HTML][HTML] ROX index as predictor of high flow nasal cannula therapy success in acute respiratory failure due to SARS-CoV-2
S Ferrer, J Sancho, I Bocigas, E Bures, H Mora… - Respiratory …, 2021 - Elsevier
Abstract Background High-Flow Nasal Cannula (HFNC) therapy is useful treatment in
patients with acute respiratory failure (ARF). The ROX index (ratio of pulse oximetry/fraction …
patients with acute respiratory failure (ARF). The ROX index (ratio of pulse oximetry/fraction …
Monoclonal antibody therapies in the management of SARS-CoV-2 infection
E Miguez-Rey, D Choi, S Kim, S Yoon… - Expert Opinion on …, 2022 - Taylor & Francis
ABSTRACT Introduction Neutralizing antibodies (NAbs) that target key domains of the spike
protein in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may have …
protein in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may have …
Prolonged higher dose methylprednisolone versus conventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS)
F Salton, P Confalonieri, S Centanni… - European …, 2023 - Eur Respiratory Soc
Background Dysregulated systemic inflammation is the primary driver of mortality in severe
coronavirus disease 2019 (COVID-19) pneumonia. Current guidelines favour a 7–10-day …
coronavirus disease 2019 (COVID-19) pneumonia. Current guidelines favour a 7–10-day …
Melatonin as a potential adjuvant treatment for COVID-19 beyond sleep disorders
A Wichniak, A Kania, M Siemiński… - International Journal of …, 2021 - mdpi.com
Melatonin is registered to treat circadian rhythm sleep–wake disorders and insomnia in
patients aged 55 years and over. The essential role of the circadian sleep rhythm in the …
patients aged 55 years and over. The essential role of the circadian sleep rhythm in the …
The pathogenesis, epidemiology and biomarkers of susceptibility of pulmonary fibrosis in COVID-19 survivors
A Vianello, G Guarnieri, F Braccioni… - Clinical Chemistry and …, 2022 - degruyter.com
Pulmonary fibrosis (PF), a pathological outcome of chronic and acute interstitial lung
diseases associated to compromised wound healing, is a key component of the “post-acute …
diseases associated to compromised wound healing, is a key component of the “post-acute …
Major candidate variables to guide personalised treatment with steroids in critically ill patients with COVID-19: CIBERESUCICOVID study
A Torres, A Motos, C Cillóniz, A Ceccato… - Intensive care …, 2022 - Springer
Purpose Although there is evidence supporting the benefits of corticosteroids in patients
affected with severe coronavirus disease 2019 (COVID-19), there is little information related …
affected with severe coronavirus disease 2019 (COVID-19), there is little information related …
[HTML][HTML] COVID-19 pandemic: lessons learned from more than a century of pandemics and current vaccine development for pandemic control
P Buchy, Y Buisson, O Cintra, DE Dwyer… - International Journal of …, 2021 - Elsevier
Pandemic dynamics and health care responses are markedly different during the COVID-19
pandemic than in earlier outbreaks. Compared with established infectious disease such as …
pandemic than in earlier outbreaks. Compared with established infectious disease such as …
Elevated plasma levels of epithelial and endothelial cell markers in COVID-19 survivors with reduced lung diffusing capacity six months after hospital discharge
Background Some COVID-19 survivors present lung function abnormalities during follow-up,
particularly reduced carbon monoxide lung diffusing capacity (DLCO). To investigate risk …
particularly reduced carbon monoxide lung diffusing capacity (DLCO). To investigate risk …